These two ASX shares couldn’t be more different, yet both make sense to me heading into 2026. The post Why I think CSL and ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

Here's what to expect from the Australian-based global biotechnology company this year. The post Prediction: CSL shares could soar past $270 in 2026 appeared first on The Motley Fool Australia.

Antares' Nick Pashias shares his picks for the ASX sector, asset class and contrarian stock bets investors might be missing ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Markets fared ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But in any portfolio, there are likely to be some stocks that fall short of that benchmark.

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine subsidiary in a wide-ranging restructure. The Melbourne-headquartered company will ...

With a new CEO, a new subsidiary, a newly approved gene therapy and three R&D centers under construction on three different continents, change is coming fast for CSL Limited. Established more than a ...